Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Bicara Therapeutics Inc.

Contributing Author

Recent Articles by Bicara Therapeutics Inc.

Aug-14
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BCAX GlobeNewswire
Aug-11
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth BCAX -14.32% GlobeNewswire
Aug-04
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET BCAX GlobeNewswire
Jul-28
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors BCAX GlobeNewswire
Jul-02
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BCAX GlobeNewswire
May-21
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC BCAX GlobeNewswire
May-13
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BCAX -6.21% GlobeNewswire
May-11
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update BCAX GlobeNewswire
May-04
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET BCAX GlobeNewswire
Apr-03
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BCAX GlobeNewswire
Mar-30
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update BCAX GlobeNewswire
Mar-23
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET BCAX GlobeNewswire
Mar-04
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BCAX GlobeNewswire
Feb-26
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares BCAX GlobeNewswire
Feb-24
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants BCAX +7.82% GlobeNewswire
Feb-24
Bicara Therapeutics Announces Proposed Public Offering of Common Stock BCAX BCAX +7.82% GlobeNewswire
Feb-23
Bicara Therapeutics to Participate in Upcoming Investor Conferences BCAX +5.94% GlobeNewswire
Feb-19
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen BCAX +6.42% GlobeNewswire
Feb-05
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BCAX -7.76% GlobeNewswire
Jan-12
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook BCAX GlobeNewswire
Dec-15
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 BCAX GlobeNewswire
Dec-06
Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 BCAX GlobeNewswire
Dec-01
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 BCAX -6.63% GlobeNewswire
Nov-10
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update BCAX GlobeNewswire
Oct-13
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC BCAX GlobeNewswire
Aug-27
Bicara Therapeutics to Participate in Upcoming Investor Conferences BCAX GlobeNewswire
Aug-12
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update BCAX GlobeNewswire
Jun-03
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference BCAX +11.21% GlobeNewswire
Jun-01
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 BCAX GlobeNewswire
May-22
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting BCAX +7.33% BCAX -40.80% GlobeNewswire
May-13
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update BCAX -8.10% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)